LL-37 — Research Peptide

Cathelicidins are a conserved family of antimicrobial peptides (AMPs) found across vertebrate species. In humans, the CAMP gene encodes the single cathelicidin precursor, hCAP18, which is enzymatically cleaved by serine proteases — most notably proteinase 3 in neutrophils and kallikreins in skin — to release the active 37-amino-acid peptide LL-37. The name reflects its structure: 37 residues beginning with two leucines.

For in-vitro laboratory research use only. Not for human consumption.

Structural Features

LL-37 is a linear, cationic peptide that adopts an amphipathic α-helical conformation in the presence of membranes or anionic environments. Key structural notes:

• 37 amino acids, net positive charge at physiological pH
• Amphipathic helix segregates hydrophobic and cationic faces
• Random coil in dilute aqueous solution, helical when membrane-bound
• Sensitive to proteolytic degradation — itself a regulated mechanism in vivo

Cellular Sources

Research has identified multiple cell types that express hCAP18 and release LL-37:

• Neutrophils — stored in secondary granules; released during degranulation
• Monocytes and macrophages
• Natural killer (NK) cells
• Epithelial cells — skin keratinocytes, airway and gut epithelium
• Mast cells

This broad expression profile places LL-37 at barrier surfaces and inflammatory sites, which is one reason it has become a focal point in innate-immunity research.

Research Domain 1: Antimicrobial Activity

The most extensively characterized property of LL-37 in vitro is its direct antimicrobial activity against a broad spectrum of organisms — Gram-positive and Gram-negative bacteria, enveloped viruses, fungi, and certain parasites. Proposed mechanisms include:

• Membrane disruption via carpet or toroidal-pore models on negatively charged microbial membranes
• Intracellular target engagement following membrane translocation
• Biofilm modulation — both inhibition of biofilm formation and disruption of mature biofilms in some experimental systems

Activity is influenced by salt concentration, serum proteins, and lipoprotein binding — frequent subjects of structure-activity research.

Research Domain 2: Immunomodulation

Beyond direct microbial killing, LL-37 has been studied as an immunomodulatory peptide. Reported in vitro and animal-model observations include:

• Chemotactic activity for neutrophils, monocytes, and T cells via the FPR2 receptor
• Modulation of TLR signaling and cytokine production
• Influence on dendritic cell differentiation
• Interaction with extracellular DNA — relevant to autoimmunity and lupus research models

Research Domain 3: Wound Healing and Epithelial Repair

Cutaneous expression of LL-37 increases at wound sites, and preclinical studies have examined its role in:

• Keratinocyte migration and proliferation
• Angiogenesis through EGFR transactivation pathways
• Re-epithelialization kinetics in animal wound models

Chronic-wound research has noted altered LL-37 expression in non-healing wounds, driving further investigation.

Research Domain 4: Cancer Biology Investigations

LL-37 expression has been reported in multiple tumor types, with context-dependent effects observed in preclinical models — proliferative in some systems, pro-apoptotic in others. This dual behavior is an active mechanistic research area.

Laboratory Handling Notes

• Supplied as a lyophilized powder
• Sensitive to oxidation and proteolysis
• Stability and activity in vitro depend strongly on buffer composition, ionic strength, and serum components
• Store per the supplied COA conditions

Frequently Asked Questions

What is LL-37?

The active 37-amino-acid peptide cleaved from the human cathelicidin precursor hCAP18, encoded by the CAMP gene. It is the only known human cathelicidin-derived AMP.

Where is LL-37 expressed in the body?

Primarily in neutrophils, monocytes, NK cells, mast cells, and epithelial surfaces including skin, airway, and gut.

What research areas focus on LL-37?

Antimicrobial activity, innate-immune modulation, wound healing, and context-dependent roles in cancer biology.

Is LL-37 for human use?

No. Sold for research purposes only. Not intended for human consumption.

For research use only — not for human consumption.

Deeper Mechanistic Insights: Membrane Interaction and Disruption

The antimicrobial action of LL-37 is fundamentally tied to its physical interaction with microbial membranes. While the initial attraction is electrostatic—the cationic peptide binding to the anionic surface of bacterial membranes—the subsequent steps that lead to membrane permeabilization and cell death are complex. Multiple models have been proposed based on biophysical studies, with the peptide's behavior depending on its concentration, the lipid composition of the target membrane, and the experimental conditions.

The Carpet Model

This is one of the most widely accepted models for LL-37's action, particularly at high peptide-to-lipid ratios. In this mechanism, LL-37 peptides do not insert deeply into the membrane core initially. Instead, they accumulate on the surface of the outer leaflet, oriented parallel to the membrane plane.

1. Electrostatic Binding: Positively charged residues on LL-37 (lysines and arginines) interact strongly with negatively charged components of microbial membranes, such as lipopolysaccharide (LPS) in Gram-negative bacteria and lipoteichoic acid (LTA) in Gram-positive bacteria, as well as phospholipids like phosphatidylglycerol (PG) and cardiolipin (CL).
2. Surface Accumulation: As more peptides bind, they form a "carpet" or layer covering a region of the membrane. This process disrupts the local organization and packing of the lipid headgroups.
3. Detergent-Like Effect: At a critical threshold concentration, the accumulated peptide layer induces significant strain on the membrane. This leads to a detergent-like effect where the membrane disintegrates into micelle-like structures, causing catastrophic leakage of cellular contents and rapid cell death.

The key feature of the carpet model is that it does not require the formation of stable, ordered protein-lined pores. This may explain LL-37's broad activity, as it relies on a general physicochemical disruption rather than a specific fit into a particular membrane structure. Research by Oren et al. (1999) using model membrane systems provided early and compelling evidence for this mode of action.

The Toroidal Pore Model

At lower peptide-to-lipid ratios, LL-37 may act via the toroidal pore model. This mechanism involves the insertion of the peptide into the membrane to form transient, water-filled channels.

1. Initial Binding and Insertion: Similar to the carpet model, LL-37 first binds to the membrane surface. However, instead of remaining parallel, the peptides insert into the lipid bilayer.
2. Induction of Membrane Curvature: The amphipathic nature of the LL-37 α-helix is key. The hydrophobic face interacts with the lipid acyl chains, while the hydrophilic, cationic face remains associated with the lipid headgroups. This arrangement induces a high degree of positive membrane curvature, causing the lipid monolayers to bend inward continuously from the outer leaflet to the inner leaflet.
3. Pore Formation: This lipid bending forms the lining of a pore, with the peptide molecules stabilizing the curved edge. The pore is thus a "toroidal" structure, a hybrid of lipid and peptide. Ions and water can pass through this channel, dissipating the electrochemical gradients essential for microbial viability.

Unlike the "barrel-stave" model (where peptides form a barrel-like structure with their hydrophobic faces outward), the toroidal pore model explains why lipids can sometimes be observed to translocate or "flip-flop" between leaflets, as the pore lining itself is composed of lipid headgroups. This model helps to explain the graded leakage of cellular contents often observed in vitro.

Intracellular Targeting

It is crucial for researchers to recognize that LL-37's activity is not always limited to the cell membrane. Once the membrane is permeabilized via the mechanisms above, or if the peptide is actively translocated at sub-lytic concentrations, it can access the microbial cytoplasm and interfere with essential intracellular processes. In-vitro studies have suggested that LL-37 can:

• Bind to DNA and RNA: The cationic nature of LL-37 allows it to bind to anionic nucleic acids, potentially inhibiting replication, transcription, and translation. This has been demonstrated in cell-free assays and in bacterial models (Nilsen & Myrnes, 2017).
• Inhibit Enzyme Activity: There is evidence that LL-37 can interfere with specific metabolic enzymes, further contributing to its bactericidal effects.
• Disrupt Ribosome Function: Research has pointed towards the inhibition of protein synthesis as another potential intracellular target, compounding the stress on the bacterial cell.

The ability to engage intracellular targets highlights LL-37 as a multi-modal antimicrobial agent, a property that may reduce the likelihood of resistance developing to any single mechanism.

Molecular Signaling Pathways Modulated by LL-37

Beyond its direct antimicrobial functions, LL-37 is a potent signaling molecule that modulates host cell responses, particularly within the innate immune system. It acts as an alarmin, a host-derived molecule that signals cellular stress or damage. Its immunomodulatory effects are primarily mediated through interactions with specific cell surface receptors and signaling pathways. For in-vitro research, understanding these pathways is critical to interpreting data from cell culture experiments involving immune cells, keratinocytes, or endothelial cells.

Formyl Peptide Receptor 2 (FPR2/ALX) Axis

One of the most significant receptors for LL-37 is the Formyl Peptide Receptor 2, also known as FPRL1 or ALX. This G-protein coupled receptor (GPCR) is expressed on a variety of immune cells, including neutrophils, monocytes, and mast cells, as well as on non-immune cells like epithelial and endothelial cells.

• Ligand Binding and GPCR Activation: When LL-37 binds to FPR2, it induces a conformational change in the receptor, leading to the activation of associated heterotrimeric G-proteins (typically of the Gαi family).
• Downstream Signaling Cascades: Activation of Gαi inhibits adenylyl cyclase, reducing cAMP levels. More importantly, the released Gβγ subunits activate multiple downstream pathways:
  • Phospholipase C (PLC): Gβγ activates PLC, which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG).
  • Calcium Mobilization: IP3 binds to receptors on the endoplasmic reticulum, triggering the release of intracellular calcium (Ca2+). This calcium flux is a critical second messenger in many cellular processes.
  • MAPK Pathway: The signaling cascade often engages the mitogen-activated protein kinase (MAPK) pathways, including ERK1/2, p38, and JNK. Activation of these kinases leads to the phosphorylation and activation of various transcription factors.
• Functional Outcomes in Research Models: In vitro, FPR2-mediated signaling by LL-37 has been shown to induce:
  • Chemotaxis: The directed migration of neutrophils and monocytes towards the source of LL-37.
  • Cytokine and Chemokine Production: Modulation of inflammatory mediator release.
  • Cell Proliferation and Angiogenesis: In epithelial and endothelial cell models, FPR2 activation can promote proliferation and tube formation, respectively, by transactivating other receptors like the Epidermal Growth Factor Receptor (EGFR).

The work of De Yang et al. (2000) was foundational in identifying FPR2 as a key receptor for LL-37, paving the way for extensive research into its role in cell trafficking and inflammation.

Toll-Like Receptor (TLR) Modulation

Toll-Like Receptors are a cornerstone of innate immunity, recognizing conserved pathogen-associated molecular patterns (PAMPs). LL-37 exhibits a complex, dual role in modulating TLR signaling. Its effect is highly context-dependent, a critical variable for researchers to control in their experiments.

• Pro-inflammatory Role: LL-37 can complex with self-DNA and self-RNA released from damaged host cells. These LL-37/nucleic acid complexes are then recognized by endosomal TLRs, specifically TLR9 (which recognizes CpG DNA) and TLR7/8 (which recognizes single-stranded RNA). In this context, LL-37 acts as a delivery vehicle, protecting the nucleic acids from degradation and facilitating their uptake and delivery to the endosomal compartment where the TLRs reside. This leads to a potent type I interferon response from plasmacytoid dendritic cells, a phenomenon studied extensively in models of autoimmune diseases like psoriasis and lupus (Lande et al., 2007).
• Anti-inflammatory Role: Conversely, LL-37 can also suppress TLR signaling. In the context of bacterial infection, LL-37 can directly bind to and neutralize lipopolysaccharide (LPS), the PAMP recognized by TLR4. By sequestering LPS, LL-37 prevents it from binding to the TLR4/MD-2/CD14 receptor complex, thereby blunting the subsequent pro-inflammatory cytokine storm (e.g., TNF-α, IL-6). This has been observed in monocyte and macrophage cell culture models.

Researchers must therefore carefully consider the experimental milieu. The presence of extracellular DNA/RNA versus the presence of bacterial PAMPs like LPS will dictate whether LL-37 drives a pro- or anti-inflammatory response via TLR pathways.

Epidermal Growth Factor Receptor (EGFR) Transactivation

In the context of wound healing and epithelial repair, a key mechanism investigated in vitro is the ability of LL-37 to transactivate the EGFR. This process links a GPCR signal (from FPR2) to a receptor tyrosine kinase (RTK) pathway without direct EGFR ligand binding.

1. LL-37 binds to FPR2 on a keratinocyte or epithelial cell.
2. The resulting G-protein signaling cascade leads to the activation of matrix metalloproteinases (MMPs) at the cell surface.
3. These MMPs cleave pro-heparin-binding EGF-like growth factor (pro-HB-EGF) anchored on the cell surface, releasing the soluble, active HB-EGF ligand.
4. The released HB-EGF then binds to and activates the nearby EGFR in an autocrine or paracrine fashion.
5. EGFR activation initiates its own downstream signaling, primarily through the Ras/Raf/MEK/ERK and PI3K/Akt pathways, promoting cell migration, proliferation, and survival—all key processes in re-epithelialization studied in scratch wound assays in vitro.

This indirect activation mechanism (Tjabringa et al., 2007) demonstrates the sophisticated integration of signaling networks that LL-37 can orchestrate, connecting innate immunity with tissue repair processes.

Quality Assurance and Sourcing for Research-Grade Peptides

For any in-vitro investigation, the quality, purity, and characterization of the reagents are paramount to generating reproducible and reliable data. This is especially true for biologically active peptides like LL-37. Researchers should demand and critically evaluate the analytical data accompanying any synthetic peptide.

Interpreting the Certificate of Analysis (COA)

A comprehensive Certificate of Analysis (COA) is the primary document certifying the quality of a research peptide. For LL-37, a researcher should expect to see the following key parameters clearly reported:

• Peptide Purity (HPLC): This is arguably the most critical parameter. It is reported as a percentage (e.g., >95%, >98%) and indicates the proportion of the target peptide relative to all other peptide-related impurities (e.g., deletion sequences, incompletely deprotected sequences) detected by HPLC, typically at a wavelength of ~214 nm. Higher purity minimizes confounding effects from contaminants in sensitive cellular assays.
• Identity Confirmation (MS): This confirms that the synthetic peptide has the correct molecular weight corresponding to the amino acid sequence of LL-37 ([M+H]⁺ ≈ 4493.3 Da). Mass spectrometry (MS) provides unambiguous verification of identity. The COA should show the theoretical mass and the observed mass.
• Peptide Content (or Net Peptide): This is a distinct and often misunderstood parameter. Lyophilized peptides are not 100% peptide; they also contain counterions (see below) and bound water. Peptide content, determined by amino acid analysis (AAA) or quantitative NMR (qNMR), quantifies the actual weight percentage of peptide in the vial. A peptide with 98% HPLC purity might only have 75% peptide content. This value is essential for accurately calculating molar concentrations for preparing stock solutions. Without it, researchers may be consistently under-dosing their experiments.
• Counterion Content (TFA): Synthetic peptides are typically purified by reverse-phase HPLC using trifluoroacetic acid (TFA) in the mobile phase. As a result, the final lyophilized product is a TFA salt. The COA may report the weight percentage of TFA. High TFA content can lower the pH of stock solutions and may have confounding biological effects in some sensitive cell culture systems.
• Appearance: A simple visual confirmation that the product is a white, lyophilized solid as expected.

Synthesis, Purification, and Logistics

The journey of a research peptide from chemical precursors to a laboratory bench involves several critical steps that determine its final quality.

• Solid-Phase Peptide Synthesis (SPPS): LL-37 is built one amino acid at a time on a solid resin support. The quality of the raw materials (amino acids, coupling reagents) and the efficiency of each coupling and deprotection step are crucial for maximizing the yield of the correct full-length sequence.
• Cleavage and Deprotection: After synthesis, the peptide is cleaved from the resin and all side-chain protecting groups are removed, typically using a strong acid cocktail (e.g., containing TFA). This step generates the crude peptide mixture.
• RP-HPLC Purification: The crude product is purified using preparative reverse-phase high-performance liquid chromatography (RP-HPLC). This separates the full-length target peptide from shorter sequences, failed sequences, and other impurities. The precision of this step directly determines the final HPLC purity.
• Lyophilization (Freeze-Drying): The purified peptide fractions, dissolved in an aqueous/acetonitrile/TFA mixture, are freeze-dried. This process removes the solvent, yielding a stable, fluffy, lyophilized powder that is suitable for long-term storage and shipping.
• Cold-Chain Shipping: LL-37, like many peptides, is susceptible to degradation over time, especially at elevated temperatures. To ensure the material arrives at the research laboratory with its integrity intact, it must be shipped under controlled cold-chain conditions (e.g., in insulated containers with cold packs). Maintaining this cold chain from our facility to the researcher's freezer is a critical final step in our quality commitment.

For inquiries about our specific quality control procedures or batch-specific data, please contact our scientific support team at info@excaliburpeptides.com.

Comparative Analysis: LL-37 vs. Other Host Defense Peptides

To better contextualize the research applications of LL-37, it is useful to compare its properties to other well-studied families of host defense peptides (HDPs). The table below provides a comparative overview for in-vitro research planning.

In-Vitro Handling and Reconstitution for Experimental Assays

Proper handling and preparation of lyophilized LL-37 peptide are essential for obtaining consistent and meaningful results in any laboratory experiment. The following guidelines are provided for research purposes only and are intended for use in a controlled laboratory setting.

Disclaimer: These instructions are for in-vitro research applications only. They are not instructions for any form of human or animal use. All handling should be performed in a suitable laboratory environment by trained personnel.

Materials and Reagents

• Lyophilized LL-37 peptide vial
• Sterile, nuclease-free, and pyrogen-free water (e.g., cell culture grade water) or a suitable sterile buffer (e.g., PBS)
• Low-protein-binding microcentrifuge tubes for aliquoting
• Calibrated micropipettes with sterile, low-retention tips

Reconstitution Procedure to Create a Stock Solution

1. Equilibration: Before opening, allow the vial of lyophilized peptide to equilibrate to room temperature for 15-20 minutes. This prevents condensation of atmospheric moisture onto the peptide powder, which can affect weighing and stability.
2. Solvent Selection: The primary recommended solvent for initial reconstitution of LL-37 is sterile, high-purity water. Due to its amphipathic nature, LL-37 can be "sticky" and may have poor solubility in salt-containing buffers initially. Reconstituting in pure water to a concentrated stock (e.g., 1-5 mg/mL) is often the most reliable method. Avoid using organic solvents like DMSO unless specifically required and validated for your assay, as they may disrupt peptide structure and can be cytotoxic in cell-based assays.
3. Calculation: Determine the volume of solvent needed. Crucially, use the Net Peptide Content value from the COA for this calculation, not the total lyophilized powder weight.
   • Example Calculation: To make a 1 mg/mL (1000 µg/mL) stock solution from a vial containing 1 mg of lyophilized powder with a net peptide content of 80% (0.8 mg of actual peptide):
     • Volume (mL) = Amount of peptide (mg) / Desired Concentration (mg/mL) = 0.8 mg / 1 mg/mL = 0.8 mL (or 800 µL).
4. Dissolution: Carefully add the calculated volume of sterile water to the vial. Replace the cap and gently agitate or vortex briefly to dissolve the powder. Visually inspect to ensure complete dissolution. Do not sonicate extensively, as it may cause aggregation or heating. If solubility is an issue, a very small amount of acid (e.g., 0.1% acetic acid) can be used, but this will lower the pH and must be accounted for in downstream experimental design.
5. Aliquoting and Storage: Immediately after reconstitution, it is highly recommended to aliquot the stock solution into smaller, single-use volumes in low-protein-binding tubes. This is critical to avoid repeated freeze-thaw cycles, which can degrade the peptide and lead to aggregation.
   • Short-term storage: Stock solutions can be stored at 2-8°C for a few days, depending on the buffer and concentration.
   • Long-term storage: For long-term preservation, snap-freeze the aliquots and store them at -20°C or, preferably, -80°C. Stored correctly, aliquots should be stable for several months.

Considerations for In-Vitro Assays

• Final Buffer Compatibility: When diluting the aqueous stock solution into your final assay buffer (e.g., cell culture medium, bacterial growth medium), be aware of potential precipitation, especially in high-salt buffers. It is good practice to add the concentrated peptide stock to the larger volume of assay buffer and mix immediately.
• Adsorption to Surfaces: LL-37 is a cationic and hydrophobic peptide, making it prone to adsorbing to the surfaces of standard plastic labware (e.g., polypropylene tubes, pipette tips, multi-well plates). This can significantly reduce the effective concentration of the peptide in your assay. To mitigate this:
  • Use low-protein-binding plasticware whenever possible.
  • In cell culture assays, serum proteins (like albumin) can help to reduce non-specific binding, but they may also sequester LL-37, affecting its bioactivity. This interaction should be considered when interpreting results.
  • For highly sensitive biophysical assays, pre-coating labware with a blocking agent like bovine serum albumin (BSA) or using siliconized tubes may be necessary.

Expanded Frequently Asked Questions

How does salt concentration affect LL-37's antimicrobial activity in vitro?

The antimicrobial activity of LL-37 is generally attenuated at high salt concentrations (e.g., physiological levels of ~150 mM NaCl). The initial step of LL-37's action is the electrostatic attraction between the cationic peptide and the anionic bacterial membrane. High concentrations of cations (like Na⁺) in the assay buffer can shield the negative charges on the bacterial surface, weakening this initial binding and thus reducing the peptide's efficacy. This is a critical factor to consider when comparing results from low-salt buffers (e.g., in a minimal inhibitory concentration, MIC, assay) versus more complex, salt-rich media (e.g., cell culture medium).

What is the significance of LL-37 being an α-helical peptide?

The adoption of an amphipathic α-helical structure upon membrane interaction is central to LL-37's function. In this conformation, the peptide arranges its amino acid side chains so that one face of the helix is hydrophobic (leucine, phenylalanine, etc.) and the opposing face is hydrophilic and cationic (lysine, arginine). This segregation allows the hydrophobic face to insert into the lipid core of the microbial membrane while the cationic face interacts with the charged lipid headgroups, facilitating the membrane disruption described by the toroidal pore and carpet models.

Why is LL-37 research challenging in vitro?

Several properties make LL-37 a challenging molecule for laboratory study. First, its "stickiness" (propensity to adsorb to plasticware) can lead to loss of material and inaccurate concentration calculations. Second, its activity is highly context-dependent, influenced by salt, pH, and the presence of other biomolecules like serum proteins or DNA. Third, as a linear peptide, it is susceptible to degradation by proteases that may be present in cell culture media (e.g., from serum) or released by cells. Researchers must implement careful controls to account for these factors.

Can LL-37 distinguish between microbial and mammalian cell membranes?

Yes, to a significant degree. This selectivity is a hallmark of many antimicrobial peptides. The primary basis for this distinction is membrane composition. Bacterial membranes are typically rich in anionic phospholipids (like PG) and lack cholesterol. In contrast, the outer leaflet of mammalian cell membranes is composed predominantly of zwitterionic phospholipids (like PC and sphingomyelin) and is rich in cholesterol. The net negative charge of microbial membranes promotes strong electrostatic binding of cationic LL-37, whereas the neutral charge and higher rigidity (due to cholesterol) of mammalian membranes make them a much less favorable target for disruption.

What is the role of the two leucines at the N-terminus of LL-37?

The name "LL-37" comes from the two leucine residues at positions 1 and 2. Structural studies suggest that the N-terminal region is important for the peptide's ability to self-associate and for its membrane-disruptive activities. Research involving N-terminally truncated or modified versions of LL-37 has shown altered antimicrobial and immunomodulatory properties, indicating this region is a key determinant of its multifaceted functions.

Are there other cathelicidins in humans?

No. While the cathelicidin gene family is large and diverse across vertebrates (e.g., pigs have many, like PR-39 and protegrins), the human genome contains only one cathelicidin gene, CAMP. This gene produces the hCAP18 precursor, from which LL-37 is the sole known active peptide fragment released. This makes LL-37 a uniquely important component of human innate immunity.

How is LL-37 expression regulated in vitro?

In cell culture models, the expression of the CAMP gene (encoding the LL-37 precursor) is known to be regulated by several factors. Vitamin D, via the vitamin D receptor (VDR), is a potent inducer of CAMP expression in many cell types, including monocytes and epithelial cells. Other stimuli, such as bacterial components (LPS) or certain cytokines (e.g., IL-1β), can also upregulate its expression, highlighting its role as an inducible defense molecule.

What is the difference between peptide purity and peptide content?

This is a critical distinction for quantitative research. Purity, measured by HPLC, refers to the percentage of the target peptide sequence relative to other peptide-related impurities. Peptide content (or net peptide weight) refers to the percentage of actual peptide mass relative to the total mass in the vial, which also includes counterions (like TFA from purification) and water. A sample can have >99% purity but only 70% peptide content. For accurate molar concentration calculations, the peptide content value is essential.

Glossary of Technical Terms

• Alarmin: A host-derived molecule released upon cellular stress or damage that acts as an endogenous danger signal to alert and activate the immune system.
• Amphipathic: A molecule containing both hydrophobic (water-repelling) and hydrophilic (water-attracting) regions.
• Angiogenesis: The physiological process through which new blood vessels form from pre-existing vessels.
• Cationic: Possessing a net positive electrical charge at neutral pH, typically due to an abundance of basic amino acids like lysine and arginine.
• Chemotaxis: The directed movement of a motile cell or organism in response to a chemical concentration gradient.
• Counterion: An ion that accompanies an ionic species in order to maintain electric neutrality. For synthetic peptides purified with TFA, the trifluoroacetate anion is the counterion to the cationic peptide.
• Endotoxin: A lipopolysaccharide (LPS) component of the outer membrane of Gram-negative bacteria, which can trigger strong inflammatory responses. LAL assays are used to detect its presence.
• FPR2 (Formyl Peptide Receptor 2): A G-protein coupled receptor on immune and epithelial cells that binds LL-37, mediating many of its immunomodulatory effects like chemotaxis.
• G-Protein Coupled Receptor (GPCR): A large family of transmembrane receptors that sense molecules outside the cell and activate inside signal transduction pathways, ultimately leading to cellular responses.
• Lipopolysaccharide (LPS): A major component of the outer membrane of Gram-negative bacteria. Also known as endotoxin.
• Lyophilization: A freeze-drying process used to remove water from a product, resulting in a stable powder that can be stored for extended periods and easily reconstituted.
• Mass Spectrometry (MS): An analytical technique that measures the mass-to-charge ratio of ions, used to confirm the molecular weight and thus the identity of a peptide.
• Minimal Inhibitory Concentration (MIC): The lowest concentration of an antimicrobial agent that prevents the visible growth of a microorganism in an in-vitro assay.
• Solid-Phase Peptide Synthesis (SPPS): A method in which a peptide chain is assembled step-by-step while one end is attached to an insoluble resin support.
• Toll-Like Receptor (TLR): A class of proteins that play a key role in the innate immune system by recognizing conserved molecular patterns on pathogens.

References

• Burton, M. F., & Steel, P. G. (2009). The chemistry and biology of LL-37. Natural Product Reports, 26(12), 1572-1584.
• De Yang, D., Chen, Q., Schmidt, A. P., Anderson, G. M., Wang, J. M., Wooters, J., ... & Oppenheim, J. J. (2000). LL-37, the neutrophil granule-and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract neutrophils, monocytes, and T cells. The Journal of Experimental Medicine, 192(7), 1069-1074.
• Lande, R., Gregorio, J., Facchinetti, V., Chatterji, B., Wang, Y. H., Homey, B., ... & Gilliet, M. (2007). Plasmacytoid dendritic cells sense self-DNA complexed with antimicrobial peptide. Nature, 449(7162), 564-569.
• Nilsen, L. E., & Myrnes, B. (2017). The human antimicrobial peptide LL-37 discriminate between nucleic acids. FEBS Open Bio, 7(9), 1335-1345.
• Oren, Z., Lerman, J. C., Gudmundsson, G. H., Agerberth, B., & Shai, Y. (1999). Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochemical Journal, 341(3), 501-513.
• Tjabringa, S., Ninaber, D. K., Drijfhout, J. W., Rabe, K. F., & Hiemstra, P. S. (2007). The human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptor-like 1. International Archives of Allergy and Immunology, 140(2), 103-112.
• Vandamme, D., Landuyt, B., Luyten, W., & Schoofs, L. (2012). A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cellular Immunology, 280(1), 22-35.

This product is intended for laboratory research use only. It is not for human or veterinary use, nor for use in diagnostic or therapeutic procedures. The information provided is for educational and research informational purposes only.

Third-Party Analytical Testing: A Methodological Overview

To ensure the validity and reproducibility of in-vitro research, a thorough understanding of the analytical methods used to characterize a synthetic peptide like LL-37 is essential. While a Certificate of Analysis (COA) provides the summary data, familiarity with the underlying techniques allows researchers to critically assess the quality of their primary reagents.

High-Performance Liquid Chromatography (HPLC) for Purity Assessment

HPLC is the gold standard for assessing the purity of a synthetic peptide. In a typical reverse-phase HPLC (RP-HPLC) method, the peptide mixture is injected into a column packed with a nonpolar stationary phase (e.g., C18 silica). A mobile phase gradient, usually of increasing organic solvent (like acetonitrile) in water, is then passed through the column.

Peptides separate based on their relative hydrophobicity; less hydrophobic species (e.g., shorter, "deletion" sequences from failed synthesis steps) elute earlier, while the more hydrophobic, full-length target peptide is retained longer. A UV detector, set to a wavelength of ~214 nm where the peptide backbone bond absorbs light, measures the amount of peptide eluting over time. The result is a chromatogram with multiple peaks. Purity is calculated as the area of the main target peptide peak divided by the total area of all peptide-related peaks. For rigorous scientific work, a purity of >98% is often desired to minimize confounding variables from contaminant peptides in sensitive assays.

Mass Spectrometry (MS) for Identity Verification

While HPLC confirms purity, it does not confirm identity. Mass spectrometry is the definitive technique for verifying that the synthesized peptide has the correct molecular mass corresponding to its intended amino acid sequence. For LL-37, the theoretical monoisotopic mass is approximately 4493.3 Daltons (Da).

In Electrospray Ionization Mass Spectrometry (ESI-MS), a common technique for peptides, the reconstituted sample is aerosolized and ionized, creating charged molecules ([M+nH]ⁿ⁺). The mass spectrometer then separates these ions based on their mass-to-charge ratio (m/z). The resulting spectrum shows a series of peaks, which can be computationally deconvoluted to determine the parent molecular mass of the peptide. A match between the observed mass and the theoretical mass provides unambiguous confirmation of the peptide's identity.

Limulus Amebocyte Lysate (LAL) Assay for Endotoxin Control

Endotoxins, primarily lipopolysaccharides (LPS) from the cell walls of Gram-negative bacteria, are potent immune activators. Even picogram-per-milliliter concentrations of endotoxin contamination in a peptide sample can trigger strong inflammatory responses in cell culture experiments (e.g., with macrophages, monocytes, or dendritic cells), leading to false-positive results. The LAL assay is a highly sensitive test used to quantify endotoxin levels. It utilizes a clotting factor cascade from the blood of the horseshoe crab (Limulus polyphemus), which is triggered by endotoxin. The results are reported in Endotoxin Units per milligram (EU/mg). For any research involving immune cells or signaling pathways, using peptides with very low endotoxin levels is critical to ensure that the observed biological effects are attributable to the peptide itself and not to bacterial contamination.

Investigating LL-37 in In-Vitro Biofilm Models

Bacterial biofilms—communities of bacteria encased in a self-produced extracellular matrix—are a major focus of antimicrobial research due to their high tolerance to conventional antibiotics. In-vitro biofilm models are essential tools for studying the potential of agents like LL-37 to combat this challenge.

Inhibition of Biofilm Formation

A primary line of investigation is the ability of LL-37 to prevent the initial stages of biofilm formation. In a typical in-vitro assay, bacterial cultures are added to the wells of a microtiter plate along with varying concentrations of LL-37. The plates are then incubated for 24-48 hours to allow biofilm growth in the untreated control wells. After incubation, non-adherent planktonic cells are washed away, and the remaining biofilm biomass is quantified. A common method for this is staining with crystal violet, which binds to the matrix and cellular components, followed by solubilization of the dye and measurement of its absorbance. A reduction in crystal violet staining in LL-37-treated wells indicates inhibition of biofilm formation.

Disruption of Established Biofilms

A more challenging but clinically relevant scenario is the disruption of pre-existing, mature biofilms. In these experimental setups, bacteria are first allowed to form a mature biofilm on a surface (e.g., in a microtiter plate or on a coupon) over 24-72 hours. The planktonic cells are then removed, and the established biofilm is treated with LL-37. The efficacy of the treatment can be assessed in several ways:

• Biomass Reduction: Quantifying the remaining biofilm mass via crystal violet staining.
• Cell Viability: Using metabolic assays (like MTT or XTT) or colony-forming unit (CFU) counting to determine the number of living bacteria remaining within the treated biofilm.
• Microscopy: Employing techniques like confocal laser scanning microscopy (CLSM) with live/dead stains (e.g., SYTO 9 and propidium iodide) to visualize the architecture of the biofilm and the spatial distribution of killed cells.

These models are also used to study synergy, where LL-37 is co-administered with a conventional antibiotic to determine if the peptide can potentiate the antibiotic's effect and overcome biofilm-mediated resistance.

Structure-Activity Relationship (SAR) Studies: A Research Perspective

LL-37 serves not only as a subject of study but also as a template for investigating the fundamental principles of antimicrobial and immunomodulatory peptide function. Structure-activity relationship (SAR) studies, where researchers systematically modify the peptide's sequence and structure, are crucial for this line of inquiry.

Truncation and Fragment Analysis

To identify the minimal sequence required for a specific biological activity, researchers synthesize and test various truncated fragments of LL-37. For example, studies have analyzed fragments from the N-terminus, C-terminus, and the central region to map functional domains. Research by Wang et al. (2009) and others has shown that certain central fragments (e.g., KR-12) can retain potent antimicrobial activity, sometimes with reduced cytotoxicity or immunomodulatory effects compared to the full-length peptide. This approach helps to deconstruct the molecule's polypharmacology, allowing for the potential design of more specific research tools.

Amino Acid Substitution

Replacing specific amino acids is a powerful technique to probe their functional importance. Key areas of investigation include:

• Cationicity: Substituting lysine (K) and arginine (R) residues with each other or with neutral amino acids (like alanine) helps determine the importance of the net positive charge versus the specific location and type of charged residue for membrane binding and immunomodulation.
• Hydrophobicity: The hydrophobic face of the LL-37 helix is crucial for membrane insertion. Substituting key hydrophobic residues (like leucine or phenylalanine) can modulate the peptide's lytic activity. Replacing them with fluorescent amino acids like tryptophan allows for biophysical studies (e.g., fluorescence spectroscopy) to directly observe the peptide's interaction with and insertion into model lipid vesicles.

Enhancing Stability for In-Vitro Assays

A significant challenge in long-term cell culture experiments (e.g., >24 hours) is the degradation of LL-37 by proteases present in serum or released by cells. To create more stable tools for such assays, researchers have synthesized modified versions of LL-37. One common strategy is to replace some or all of the L-amino acids with their D-amino acid stereoisomers. D-amino acid peptides are "mirror images" that often retain similar membrane-disruptive activity but are highly resistant to degradation by natural L-proteases. This ensures a more stable, known concentration of the peptide throughout a long-term experiment, providing more reliable data on its effects.

This product is intended for laboratory research use only. It is not for human or veterinary use, nor for use in diagnostic or therapeutic procedures. The information provided is for educational and research informational purposes only and does not constitute a recommendation for any specific application.